Antiverse, a techbio company designing antibodies for challenging targets, today announced it has added £3.5 M ($4.6 M) to its seed funding.
Innate shelves lacutamab monotherapy plans in peripheral T cell lymphoma – Pharmaceutical Technology
Share this article Innate announced the decision to not reopen the trial’s recruitment in its full-year earnings report. Image credit: Shutterstock/CI Photos. Innate has dropped